FCN3 and hepatocellular carcinoma: Furthermore, in the presence of varying doses of erastin or FINO2, both FCN3- or nsFCN3-expressing HCC cells exhibited reduced viability, with nsFCN3 overexpression leading to a higher level of cell death (Fig. 2K, L; Fig. S2J).